According to a recent LinkedIn post from Flatiron Health, the company is participating in Friends of Cancer Research’s multi-stakeholder pilot on external control arms (ECAs) in oncology. The post indicates that Flatiron is contributing real-world data to evaluate how ECAs built from existing clinical trial and real-world evidence can complement traditional control arms.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights that Flatiron and partners are showcasing proof-of-concept findings at the ISPOR Annual meeting, focusing on metastatic pancreatic cancer. This suggests ongoing investment in real-world evidence capabilities that could enhance the company’s value proposition to biopharma sponsors seeking faster, more efficient oncology drug development.
By aligning with Friends of Cancer Research and other industry collaborators, Flatiron appears to be positioning its datasets and analytics as tools to support regulatory decision-making and potentially expand patient access to new therapies. If regulators and sponsors increasingly accept ECAs, this approach could drive incremental demand for Flatiron’s data services and strengthen its competitive position in oncology RWE.
For investors, the activity described in the post points to Flatiron’s strategic emphasis on evidence-generation use cases that sit close to regulatory and health-technology assessment workflows. Successful validation of ECAs in difficult indications like metastatic pancreatic cancer could translate into deeper partnerships, higher switching costs for clients, and longer-term revenue visibility in the oncology data and analytics market.